How J&J paved the way for Compass’ coming psychedelic drug launch

RegulatoryCompass psychedelic drugSpravatoPositive

AI Analysis

Summary

Compass Pathways executives discuss strategy to commercialize their psychedelic drug if FDA-approved, drawing from J&J's approach with ketamine spray Spravato. No specific approval timeline or drug details provided.

Importance:4/10

Sentiment:

0.30

psychedelicsFDA approvalcommercial strategyketaminemental health

Related Companies

$CMPS $JNJ

Read the original article

Published by BioPharma Dive on September 21, 2026 11:30 AM

Read Original